Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Randomized Study of AZD4547 vs Paclitaxel in FGFR2‑positive Advanced Gastric Adenocarcinoma
jRCT2080221961Phase 2
- Sponsor
- AstraZeneca
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fexagratinib in gastric adenocarcinoma, esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by AstraZeneca.
02
Drugs
fexagratinib
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2080221961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221961.